Contributions
Abstract: EP1714
Type: Poster Sessions
Abstract Category: Therapy - Others
Introduction: There is little evidence regarding the real impact in satisfaction and quality of life (QoL) with new oral immunomodulatory therapies (OIT) for relapsing-remitting multiple sclerosis (RRMS).
Objective: assessment of health outcomes in patients treated with OIT (teriflunomide [TE] or dimethyl fumarate [DMF]) in a real world setting.
Patients and methods: Clinical features, QoL (MusiQoL and EuroQoL) and treatmetn saatisfaction (TSQM) were evaluated in RRMS patients treated with TE or DMF for at least 1 year.
Results: 81 patients started 88 OIT (43DMF; 45TE). 79% women; Mean age 42.22 years (SD 8.05), mean disease duration 100.64 months (SD 66.08), mean baseline EDSS 1.79 points (SD 1.87), number of relapses 1year prior: 0.75 (SD 0.87). 18 patients (22.5%) were naïve, 65 (73.5%) received at least one DMT. The main reason for change were side effects (52.3%), followed by innefficiency (19.3%) and safety (4.5%).
EQ-VAS-EuroQoL baseline (mean points±SD): 70.3±19.8, (67.9 ± 20.3 DMF; 72.3 ± 19.0 TE). The worst-rated dimmension were: anxiety / depression (31.3%), pain (25.0%) and difficulty in carrying out daily activities (12.5%) .
MusiQoL baseline (mean points; SD): 70.1 ± 14.8 (69.9 ± 15.0 for DMF vs 70.3 ± 14.9 for TE)
EQ-VAS_year 1: 68.3 ± 20.3 points, (DMF 70.3 ± 18.3 points vs TE 66.6 ± 22.11).
Mean MusiQoL_year 1: 67.9 ± 15.5 points (70.2 ± 16.7 for DMF vs. 66.1 ± 14.5 for TE)
TSQM at baseline: efficacy (62.6 ± 23.9 points), side effects (50.4 ± 24.1 points) convenience (57.4 ± 24.9 points) and overall satisfaction (62.3 ± 23.3 points) .
TSQM at year 1: efficacy (66.4 ± 23.9 points), side effects (67.7 ± 23.3 points) convenience (82.7 ± 19.1 points) and overall satisfaction (73.6 ± 17.9 points) . DMF vs TE: efficacy (69.3 ± 19.2 vs 63.6 ± 28.0), side effects (70.1 ± 22.3 vs 64.8 ± 26.7), convenience (77.5 ± 18. 6 vs 88.2 ± 18.6). The TSQM dimensions improved during treatment with TE compared to previous TI, (p < 0.05).
Conclusions: QoL seems to be mantained after one year with OIT. However, patients on OIT present increased satisfaction compared to previous IT, maybe due to a better tolerance and greater convenience in the administration. Patients on DMF have greater satisfaction in terms of efficacy and side effectscompared to TE but to a decreased convenience.
Disclosure: Inés Gonzalez Suárez have Merck, Biogen, Genzyme, Novartis.
Elena Alvarez Merck, Biogen, Genzyme, Novartis.
Miriam Alvarez Payero Merck, Sanofi-Genzyme, Biogen
Marta Aguado-Valcarcel Merck, Sanofi-Genzyme, Biogen
Guadalupe Piñeiro-Corrales Merck, Sanofi-Genzyme, Biogen, Roche
Hadriana has no potential conflicts of interests
Cesar Sanchez has no potential conflicts of interests
Abstract: EP1714
Type: Poster Sessions
Abstract Category: Therapy - Others
Introduction: There is little evidence regarding the real impact in satisfaction and quality of life (QoL) with new oral immunomodulatory therapies (OIT) for relapsing-remitting multiple sclerosis (RRMS).
Objective: assessment of health outcomes in patients treated with OIT (teriflunomide [TE] or dimethyl fumarate [DMF]) in a real world setting.
Patients and methods: Clinical features, QoL (MusiQoL and EuroQoL) and treatmetn saatisfaction (TSQM) were evaluated in RRMS patients treated with TE or DMF for at least 1 year.
Results: 81 patients started 88 OIT (43DMF; 45TE). 79% women; Mean age 42.22 years (SD 8.05), mean disease duration 100.64 months (SD 66.08), mean baseline EDSS 1.79 points (SD 1.87), number of relapses 1year prior: 0.75 (SD 0.87). 18 patients (22.5%) were naïve, 65 (73.5%) received at least one DMT. The main reason for change were side effects (52.3%), followed by innefficiency (19.3%) and safety (4.5%).
EQ-VAS-EuroQoL baseline (mean points±SD): 70.3±19.8, (67.9 ± 20.3 DMF; 72.3 ± 19.0 TE). The worst-rated dimmension were: anxiety / depression (31.3%), pain (25.0%) and difficulty in carrying out daily activities (12.5%) .
MusiQoL baseline (mean points; SD): 70.1 ± 14.8 (69.9 ± 15.0 for DMF vs 70.3 ± 14.9 for TE)
EQ-VAS_year 1: 68.3 ± 20.3 points, (DMF 70.3 ± 18.3 points vs TE 66.6 ± 22.11).
Mean MusiQoL_year 1: 67.9 ± 15.5 points (70.2 ± 16.7 for DMF vs. 66.1 ± 14.5 for TE)
TSQM at baseline: efficacy (62.6 ± 23.9 points), side effects (50.4 ± 24.1 points) convenience (57.4 ± 24.9 points) and overall satisfaction (62.3 ± 23.3 points) .
TSQM at year 1: efficacy (66.4 ± 23.9 points), side effects (67.7 ± 23.3 points) convenience (82.7 ± 19.1 points) and overall satisfaction (73.6 ± 17.9 points) . DMF vs TE: efficacy (69.3 ± 19.2 vs 63.6 ± 28.0), side effects (70.1 ± 22.3 vs 64.8 ± 26.7), convenience (77.5 ± 18. 6 vs 88.2 ± 18.6). The TSQM dimensions improved during treatment with TE compared to previous TI, (p < 0.05).
Conclusions: QoL seems to be mantained after one year with OIT. However, patients on OIT present increased satisfaction compared to previous IT, maybe due to a better tolerance and greater convenience in the administration. Patients on DMF have greater satisfaction in terms of efficacy and side effectscompared to TE but to a decreased convenience.
Disclosure: Inés Gonzalez Suárez have Merck, Biogen, Genzyme, Novartis.
Elena Alvarez Merck, Biogen, Genzyme, Novartis.
Miriam Alvarez Payero Merck, Sanofi-Genzyme, Biogen
Marta Aguado-Valcarcel Merck, Sanofi-Genzyme, Biogen
Guadalupe Piñeiro-Corrales Merck, Sanofi-Genzyme, Biogen, Roche
Hadriana has no potential conflicts of interests
Cesar Sanchez has no potential conflicts of interests